Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Dominik Selleslag, Stefan Suciu, Giovanna Meloni, Petra Muus, Constantijn J.M. Halkes, Adriano Venditti, Safaa M. Ramadan, Hans Pruijt, Liv Meert, Marco Vignetti, Jean Pierre Marie, Sébastian Wittnebel, Theo de Witte, Sergio Amadori, Roelof Willemze, Frédéric Baron

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)e47-e51
Issue number2
Publication statusPublished - Jan 1 2017

ASJC Scopus subject areas

  • Hematology

Cite this